A citation-based method for searching scientific literature

Hideyuki Arita, Kai Yamasaki, Yuko Matsushita, Taishi Nakamura, Asanao Shimokawa, Hirokazu Takami, Shota Tanaka, Akitake Mukasa, Mitsuaki Shirahata, Saki Shimizu, Kaori Suzuki, Kuniaki Saito, Keiichi Kobayashi, Fumi Higuchi, Takeo Uzuka, Ryohei Otani, Kaoru Tamura, Kazutaka Sumita, Makoto Ohno, Yasuji Miyakita, Naoki Kagawa, Naoya Hashimoto, Ryusuke Hatae, Koji Yoshimoto, Naoki Shinojima, Hideo Nakamura, Yonehiro Kanemura, Yoshiko Okita, Manabu Kinoshita, Kenichi Ishibashi, Tomoko Shofuda, Yoshinori Kodama, Kanji Mori, Yusuke Tomogane, Junya Fukai, Koji Fujita, Yuzo Terakawa, Naohiro Tsuyuguchi, Shusuke Moriuchi, Masahiro Nonaka, Hiroyoshi Suzuki, Makoto Shibuya, Taketoshi Maehara, Nobuhito Saito, Motoo Nagane, Nobutaka Kawahara, Keisuke Ueki, Toshiki Yoshimine, Etsuo Miyaoka, Ryo Nishikawa, Takashi Komori, Yoshitaka Narita, Koichi Ichimura. Acta Neuropathol Commun 2016
Times Cited: 116







List of co-cited articles
744 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery.
Patrick J Cimino, Michael Zager, Lisa McFerrin, Hans-Georg Wirsching, Hamid Bolouri, Bettina Hentschel, Andreas von Deimling, David Jones, Guido Reifenberger, Michael Weller,[...]. Acta Neuropathol Commun 2017
53
7

IDH mutation impairs histone demethylation and results in a block to cell differentiation.
Chao Lu, Patrick S Ward, Gurpreet S Kapoor, Dan Rohle, Sevin Turcan, Omar Abdel-Wahab, Christopher R Edwards, Raya Khanin, Maria E Figueroa, Ari Melnick,[...]. Nature 2012
4

Announcing cIMPACT-NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy.
David N Louis, Ken Aldape, Daniel J Brat, David Capper, David W Ellison, Cynthia Hawkins, Werner Paulus, Arie Perry, Guido Reifenberger, Dominique Figarella-Branger,[...]. Acta Neuropathol 2017
65
6

Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas.
Gang Wu, Alberto Broniscer, Troy A McEachron, Charles Lu, Barbara S Paugh, Jared Becksfort, Chunxu Qu, Li Ding, Robert Huether, Matthew Parker,[...]. Nat Genet 2012
927
4

The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials.
Maryam Moradi Binabaj, Afsane Bahrami, Soodabeh ShahidSales, Marjan Joodi, Mona Joudi Mashhad, Seyed Mahdi Hassanian, Kazem Anvari, Amir Avan. J Cell Physiol 2018
111
4

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
Dung T Le, Jennifer N Uram, Hao Wang, Bjarne R Bartlett, Holly Kemberling, Aleksandra D Eyring, Andrew D Skora, Brandon S Luber, Nilofer S Azad, Dan Laheru,[...]. N Engl J Med 2015
4

Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics.
Andrea Sottoriva, Inmaculada Spiteri, Sara G M Piccirillo, Anestis Touloumis, V Peter Collins, John C Marioni, Christina Curtis, Colin Watts, Simon Tavaré. Proc Natl Acad Sci U S A 2013
949
4

Temozolomide-associated hypermutation in gliomas.
Serah Choi, Yao Yu, Matthew R Grimmer, Michael Wahl, Susan M Chang, Joseph F Costello. Neuro Oncol 2018
55
7

MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance.
Stephen Yip, Jiangyong Miao, Daniel P Cahill, A John Iafrate, Ken Aldape, Catherine L Nutt, David N Louis. Clin Cancer Res 2009
251
4

CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015.
Quinn T Ostrom, Haley Gittleman, Gabrielle Truitt, Alexander Boscia, Carol Kruchko, Jill S Barnholtz-Sloan. Neuro Oncol 2018
797
4

Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.
Michael Weller, Jörg Felsberg, Christian Hartmann, Hilmar Berger, Joachim P Steinbach, Johannes Schramm, Manfred Westphal, Gabriele Schackert, Matthias Simon, Jörg C Tonn,[...]. J Clin Oncol 2009
421
4

Brain tumor cells in circulation are enriched for mesenchymal gene expression.
James P Sullivan, Brian V Nahed, Marissa W Madden, Samantha M Oliveira, Simeon Springer, Deepak Bhere, Andrew S Chi, Hiroaki Wakimoto, S Michael Rothenberg, Lecia V Sequist,[...]. Cancer Discov 2014
125
4

Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.
Marc Sanson, Yannick Marie, Sophie Paris, Ahmed Idbaih, Julien Laffaire, François Ducray, Soufiane El Hallani, Blandine Boisselier, Karima Mokhtari, Khe Hoang-Xuan,[...]. J Clin Oncol 2009
689
4

Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
Hyun Sik Kim, Mi Jung Kwon, Joon Ho Song, Eun Soo Kim, Ho Young Kim, Kyueng-Whan Min. Pathol Res Pract 2018
14
28


cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAFV600E mutation.
David W Ellison, Cynthia Hawkins, David T W Jones, Arzu Onar-Thomas, Stefan M Pfister, Guido Reifenberger, David N Louis. Acta Neuropathol 2019
68
5

Quantitative digital assessment of MGMT immunohistochemical expression in glioblastoma tissue.
Yukie Araki, Masahiro Mizoguchi, Koji Yoshimoto, Tadahisa Shono, Toshiyuki Amano, Akira Nakamizo, Satoshi O Suzuki, Toru Iwaki, Tomio Sasaki. Brain Tumor Pathol 2011
17
23

Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial.
Thomas Sandmann, Richard Bourgon, Josep Garcia, Congfen Li, Timothy Cloughesy, Olivier L Chinot, Wolfgang Wick, Ryo Nishikawa, Warren Mason, Roger Henriksson,[...]. J Clin Oncol 2015
179
4

Prevalence and clinicopathological features of H3.3 G34-mutant high-grade gliomas: a retrospective study of 411 consecutive glioma cases in a single institution.
Koji Yoshimoto, Ryusuke Hatae, Yuhei Sangatsuda, Satoshi O Suzuki, Nobuhiro Hata, Yojiro Akagi, Daisuke Kuga, Murata Hideki, Koji Yamashita, Osamu Togao,[...]. Brain Tumor Pathol 2017
27
14

TERT promoter mutation subtypes and survival in stage I and II melanoma patients.
Juan J Andrés-Lencina, Sivaramakrishna Rachakonda, Zaida García-Casado, Nalini Srinivas, Alexander Skorokhod, Celia Requena, Virtudes Soriano, Rajiv Kumar, Eduardo Nagore. Int J Cancer 2019
23
17

Disruption of the β1L Isoform of GABP Reverses Glioblastoma Replicative Immortality in a TERT Promoter Mutation-Dependent Manner.
Andrew Mancini, Ana Xavier-Magalhães, Wendy S Woods, Kien-Thiet Nguyen, Alexandra M Amen, Josie L Hayes, Christof Fellmann, Michael Gapinske, Andrew M McKinney, Chibo Hong,[...]. Cancer Cell 2018
46
8

TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations.
Erik A Williams, Julie J Miller, Shilpa S Tummala, Tristan Penson, A John Iafrate, Tareq A Juratli, Daniel P Cahill. Acta Neuropathol Commun 2018
9
44

CDKN2A loss is associated with shortened overall survival in lower-grade (World Health Organization Grades II-III) astrocytomas.
Gerald F Reis, Melike Pekmezci, Helen M Hansen, Terri Rice, Roxanne E Marshall, Annette M Molinaro, Joanna J Phillips, Hannes Vogel, John K Wiencke, Margaret R Wrensch,[...]. J Neuropathol Exp Neurol 2015
65
6

Mitotic Index Thresholds Do Not Predict Clinical Outcome for IDH-Mutant Astrocytoma.
Rebecca A Yoda, Troy Marxen, Lauren Longo, Chibawanye Ene, Hans-Georg Wirsching, C Dirk Keene, Eric C Holland, Patrick J Cimino. J Neuropathol Exp Neurol 2019
10
40

The epidemiology of glioma in adults: a "state of the science" review.
Quinn T Ostrom, Luc Bauchet, Faith G Davis, Isabelle Deltour, James L Fisher, Chelsea Eastman Langer, Melike Pekmezci, Judith A Schwartzbaum, Michelle C Turner, Kyle M Walsh,[...]. Neuro Oncol 2014
813
4

MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges.
Alireza Mansouri, Laureen D Hachem, Sheila Mansouri, Farshad Nassiri, Normand J Laperriere, Daniel Xia, Neal I Lindeman, Patrick Y Wen, Arnab Chakravarti, Minesh P Mehta,[...]. Neuro Oncol 2019
59
6

Current state of immunotherapy for glioblastoma.
Michael Lim, Yuanxuan Xia, Chetan Bettegowda, Michael Weller. Nat Rev Clin Oncol 2018
336
4

Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid.
Alexandra M Miller, Ronak H Shah, Elena I Pentsova, Maryam Pourmaleki, Samuel Briggs, Natalie Distefano, Youyun Zheng, Anna Skakodub, Smrutiben A Mehta, Carl Campos,[...]. Nature 2019
159
4

Diagnostic potential of TERT promoter and FGFR3 mutations in urinary cell-free DNA in upper tract urothelial carcinoma.
Yujiro Hayashi, Kazutoshi Fujita, Kyosuke Matsuzaki, Makoto Matsushita, Norihiko Kawamura, Yoko Koh, Kosuke Nakano, Cong Wang, Yu Ishizuya, Yoshiyuki Yamamoto,[...]. Cancer Sci 2019
28
14

MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials.
Monika E Hegi, Els Genbrugge, Thierry Gorlia, Roger Stupp, Mark R Gilbert, Olivier L Chinot, L Burt Nabors, Greg Jones, Wim Van Criekinge, Josef Straub,[...]. Clin Cancer Res 2019
42
9

Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas.
Craig Horbinski, Marina N Nikiforova, Jill M Hagenkord, Ronald L Hamilton, Ian F Pollack. Neuro Oncol 2012
95
3

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
David Moher, Alessandro Liberati, Jennifer Tetzlaff, Douglas G Altman. PLoS Med 2009
3

Combination genetic signature stratifies lower-grade gliomas better than histological grade.
Aden Ka-Yin Chan, Yu Yao, Zhenyu Zhang, Zhifeng Shi, Liang Chen, Nellie Yuk-Fei Chung, Joseph Shu-Ming Liu, Kay Ka-Wai Li, Danny Tat-Ming Chan, Wai Sang Poon,[...]. Oncotarget 2015
31
9

To BRAF or not to BRAF: is that even a question anymore?
Craig Horbinski. J Neuropathol Exp Neurol 2013
75
4

Biomarker-based prognostic stratification of young adult glioblastoma.
Rui-Qi Zhang, Zhifeng Shi, Hong Chen, Nellie Yuk-Fei Chung, Zi Yin, Kay Ka-Wai Li, Danny Tat-Ming Chan, Wai Sang Poon, Jinsong Wu, Liangfu Zhou,[...]. Oncotarget 2016
25
12

Pleomorphic Xanthoastrocytoma: Natural History and Long-Term Follow-Up.
Cristiane M Ida, Fausto J Rodriguez, Peter C Burger, Alissa A Caron, Sarah M Jenkins, Grant M Spears, Dawn L Aranguren, Daniel H Lachance, Caterina Giannini. Brain Pathol 2015
118
3

A three-gene signature for prognosis in patients with MGMT promoter-methylated glioblastoma.
Wen Wang, Lu Zhang, Zheng Wang, Fan Yang, Haoyuan Wang, Tingyu Liang, Fan Wu, Qing Lan, Jiangfei Wang, Jizong Zhao. Oncotarget 2016
31
9

Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial.
Ulrich Herrlinger, Niklas Schäfer, Joachim P Steinbach, Astrid Weyerbrock, Peter Hau, Roland Goldbrunner, Franziska Friedrich, Veit Rohde, Florian Ringel, Uwe Schlegel,[...]. J Clin Oncol 2016
96
3

The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone.
Remco J Molenaar, Dagmar Verbaan, Simona Lamba, Carlo Zanon, Judith W M Jeuken, Sandra H E Boots-Sprenger, Pieter Wesseling, Theo J M Hulsebos, Dirk Troost, Angela A van Tilborg,[...]. Neuro Oncol 2014
108
3

Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study.
L Burt Nabors, Karen L Fink, Tom Mikkelsen, Danica Grujicic, Rafal Tarnawski, Do Hyun Nam, Maria Mazurkiewicz, Michael Salacz, Lynn Ashby, Vittorina Zagonel,[...]. Neuro Oncol 2015
128
3

Benefits of interferon-β and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: A multicenter study.
Kazuya Motomura, Atsushi Natsume, Yugo Kishida, Hiroyuki Higashi, Yutaka Kondo, Yoko Nakasu, Tatsuya Abe, Hiroki Namba, Kenji Wakai, Toshihiko Wakabayashi. Cancer 2011
70
4

Epithelioid glioblastoma arising from pleomorphic xanthoastrocytoma with the BRAF V600E mutation.
Shingo Tanaka, Mitsutoshi Nakada, Sumihito Nobusawa, Satoshi O Suzuki, Hemragul Sabit, Katsuyoshi Miyashita, Yutaka Hayashi. Brain Tumor Pathol 2014
48
6

Epithelioid Glioblastomas and Anaplastic Epithelioid Pleomorphic Xanthoastrocytomas--Same Entity or First Cousins?
Sanda Alexandrescu, Andrey Korshunov, Siang Hui Lai, Salma Dabiri, Sushama Patil, Rong Li, Chie-Schin Shih, Jose M Bonnin, Jonathan A Baker, Emma Du,[...]. Brain Pathol 2016
63
4

Concurrent TERT promoter and BRAF V600E mutation in epithelioid glioblastoma and concomitant low-grade astrocytoma.
Nozomi Matsumura, Nozomi Nakajima, Tatsuya Yamazaki, Takuro Nagano, Kaie Kagoshima, Sumihito Nobusawa, Hayato Ikota, Hideaki Yokoo. Neuropathology 2017
30
10

Whole-genome landscapes of major melanoma subtypes.
Nicholas K Hayward, James S Wilmott, Nicola Waddell, Peter A Johansson, Matthew A Field, Katia Nones, Ann-Marie Patch, Hojabr Kakavand, Ludmil B Alexandrov, Hazel Burke,[...]. Nature 2017
521
3

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.
Lenny Dang, David W White, Stefan Gross, Bryson D Bennett, Mark A Bittinger, Edward M Driggers, Valeria R Fantin, Hyun Gyung Jang, Shengfang Jin, Marie C Keenan,[...]. Nature 2009
3

IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas.
Koichi Ichimura, Danita M Pearson, Sylvia Kocialkowski, L Magnus Bäcklund, Raymond Chan, David T W Jones, V Peter Collins. Neuro Oncol 2009
415
3

Radiotherapy for glioblastoma in the elderly.
Florence Keime-Guibert, Olivier Chinot, Luc Taillandier, Stéphanie Cartalat-Carel, Marc Frenay, Guy Kantor, Jean-Sébastien Guillamo, Eric Jadaud, Philippe Colin, Pierre-Yves Bondiau,[...]. N Engl J Med 2007
496
3

International Atomic Energy Agency Randomized Phase III Study of Radiation Therapy in Elderly and/or Frail Patients With Newly Diagnosed Glioblastoma Multiforme.
Wilson Roa, Lucyna Kepka, Narendra Kumar, Valery Sinaika, Juliana Matiello, Darejan Lomidze, Dalenda Hentati, Douglas Guedes de Castro, Katarzyna Dyttus-Cebulok, Suzanne Drodge,[...]. J Clin Oncol 2015
137
3

Radiation therapy dose escalation for glioblastoma multiforme in the era of temozolomide.
Shahed N Badiyan, Stephanie Markovina, Joseph R Simpson, Clifford G Robinson, Todd DeWees, David D Tran, Gerry Linette, Rohan Jalalizadeh, Ralph Dacey, Keith M Rich,[...]. Int J Radiat Oncol Biol Phys 2014
35
8


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.